Myelofibrosis14TARGET AUDIENCE OVERVIEW OF ACTIVITY Therapeutic options for myelofibrosis are few and provide limited benefit, with the exception of allogeneic stem cell transplantation, which may be curative but for which few patients are eligible. The JAK2 inhibitor ruxolitinib has been shown to result in reduced splenomegaly and improvement in symptoms and overall survival in patients with symptomatic myelofibrosis. Ruxolitinib is the first FDA-approved systemic therapy for myelofibrosis. However, because of the infrequency of myelofibrosis many community oncologists have limited knowledge of this disease and its management, particularly with newly emerging agents. To bridge the gap between research and patient care, this CME activity will use the perspectives of clinical investigators on key management challenges and controversies in myelofibrosis to assist medical oncologists, hematologist-oncologists, hematology-oncology fellows and other cancer clinicians in the formulation of up-to-date and appropriate treatment strategies. LEARNING OBJECTIVES
ACCREDITATION STATEMENT CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Francisco Cervantes, MD, PhD Advisory Committee: Celgene Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi, Teva Oncology; Speakers Bureau: Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation. Jorge E Cortes, MD Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc; Consulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Paid Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi. Jason Gotlib, MD, MS Advisory Committee and Contracted Research: Gilead Sciences Inc, Incyte Corporation, Novartis Pharmaceuticals Corporation, Sanofi; Travel Support: Incyte Corporation, Novartis Pharmaceuticals Corporation. Elias Jabbour, MD Consulting Agreements: Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Pfizer Inc. Hagop M Kantarjian, MD Consulting Agreement: Novartis Pharmaceuticals Corporation; Paid Research: ARIAD Pharmaceuticals Inc, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Pfizer Inc. John O Mascarenhas, MD Consulting Agreements: Incyte Corporation; Contracted Research: Celgene Corporation, Genzyme Corporation, Incyte Corporation, Novartis Pharmaceuticals Corporation. Ruben A Mesa, MD Contracted Research: Celgene Corporation, Genentech BioOncology, Lilly, Sanofi. Jerry L Spivak, MD Consulting Agreements: Celgene Corporation, Merck, Novartis Pharmaceuticals Corporation. David P Steensma, MD Advisory Committee: Astex Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Incyte Corporation, Novartis Pharmaceuticals Corporation; Consulting Agreements: Amgen Inc, Celgene Corporation. Moshe Talpaz, MD Advisory Committee: ARIAD Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Consulting Agreement: Pfizer Inc; Contracted Research: Abbott Laboratories, ARIAD Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc, Sanofi. Alessandro M Vannucchi, MD Advisory Committee: Novartis Pharmaceuticals Corporation. Srdan Verstovsek, MD, PhD Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Geron, Gilead Sciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Lilly, Novartis Pharmaceuticals Corporation, NS Pharma Inc, Promedior Inc, Roche Laboratories Inc, Seattle Genetics, YM BioSciences Inc. EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor. This activity is supported by an educational grant from Incyte Corporation. Hardware/Software Requirements: Last review date: July 2014 |